Sglt2 Inhibitor

AUSTIN, Texas — Results presented here showed that combining SGLT2 inhibitors and mineralocorticoid receptor antagonists was effective in reducing the urinary albumin creatinine ratio in patients with type 2 diabetes.

Patients with heart failure who received an SGLT2 inhibitor were less likely to experience sudden cardiac death compared with those who received placebo, according to a study in Clinical Cardiology.

SGLT2 inhibitor therapy in patients with heart failure is associated with a significantly lower incidence of sudden cardiac death vs. placebo, with the benefit persisting independent of other guideline-directed medical therapies.

Compared with glucagon-like peptide-1 receptor agonists, patients with chronic kidney disease and type 2 diabetes experienced increased risks when taking SGLT2 inhibitors, according to published data.

Researchers estimated that more than 80% of adults in the United States meet the criteria for GLP-1 receptor agonists or SGLT2 inhibitors, but only about one in 10 used either medication from 2017 to 2020.

SGLT2 inhibitors were associated with a lower risk for major adverse cardiovascular events and heart failure hospitalization compared with DPP-4 inhibitors among patients with type 2 diabetes, regardless of baseline HbA1c levels, data show

Disparities by sex, race and between individual U.S. Veterans Affairs facilities exist in SGLT2i prescriptions for veterans with chronic kidney disease, type 2 diabetes mellitus and atherosclerotic cardiovascular disease, researchers found.

The FDA approved bexagliflozin, an oral SGLT2 inhibitor, to improve glycemic control for adults with type 2 diabetes, according to a company press release.

Black and older patients with chronic kidney disease and insured by Medicare are less likely to start SGLT2 inhibitors or glucagon-like peptide 1 receptor agonists than second-generation sulfonylureas, according to data in Kidney Medicine.

Adults with type 2 diabetes may be able to reduce their liver fat and improve their liver fibrosis stage with reductions in HbA1c, according to a study published in Nutrition, Metabolism & Cardiovascular Diseases.